Evidence map›Paper›PMID 16217019›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2005

Inhibition of vagally mediated immune-to-brain signaling by vanadyl sulfate speeds recovery from sickness.

Daniel R Johnson, Jason C O'Connor, Robert Dantzer, Gregory G Freund

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Three questions about leptin and immunity.Brain, behavior, and immunity · 2009
    Review
  6. Psychoneuroimmune implications of type 2 diabetes: redux.Immunology and allergy clinics of North America · 2009
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Acute hypoxia activates the neuroimmune system, which diabetes exacerbates.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2007
    Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Daniel R JohnsonDepartment of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
Jason C O'Connor
Robert Dantzer
Gregory G Freund
Neurocentre Magendie · FRUniversity of Illinois Urbana-Champaign · US

Funding

Brain Immune Interactions In Type 2 DiabetesR01DK064862 · NIDDK · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI FREUND, GREGORY G · 2004 to 2013
$3.4M
Neuroimmunology of Behavioral and Mood DisordersR01MH071349 · NIMH · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI DANTZER, ROBERT · 2004 to 2008
$1.6M
NIDDK NIH HHS DK064862NIDDK NIH HHS R01 DK064862NIMH NIH HHS MH071349NIMH NIH HHS R01 MH071349
6 · The paper itself

Abstract

To the ill patient with diabetes, the behavioral symptoms of sickness such as fatigue and apathy are debilitating and can prevent recuperation. Here we report that peripherally administered insulin-like growth factor 1 (IGF-1) attenuates LPS-dependent depression of social exploration (sickness) in nondiabetic (db/+) but not in diabetic (db/db) mice. We show that the insulin/IGF-1 mimetic vanadyl sulfate (VS) is effective at augmenting recovery from sickness in both db/+ and db/db mice. Specifically, peak illness was reached at 2 h for both VS and control animals injected with LPS, and VS mice recovered 50% faster than non-VS-treated animals. Examination of the mechanism of VS action in db/+ mice showed that VS paradoxically augmented peritoneal macrophage responsivity to LPS, increasing both peritoneal and ex vivo macrophage production of IL-1beta and IL-6 but not TNF-alpha. The effects of VS in promoting recovery from sickness were not restricted to LPS, because they were also observed after direct administration of IL-1beta. To explore the possibility that VS impairs immune-to-brain communication via vagal afferents, the vagally mediated satiety-inducing effects of cholecystokinin 8 were tested in db/+ mice. Cholecystokinin decreased food intake in saline-injected mice but not in VS-treated mice. VS also inhibited LPS-dependent up-regulation of IL-1beta and IL-6 mRNA in the brain, while increasing by 50% the cerebral expression of transcripts of the specific antagonist of IL-1 receptors IL-1RA and IL-1R2. Taken together, these data indicate that VS improves recovery from LPS-induced sickness by blocking vagally mediated immune-to-brain signaling and by up-regulating brain expression of IL-1beta antagonists.

Indexed as

AnimalsBrainCells, CulturedCholecystokininDiabetes MellitusEatingExploratory BehaviorHumansHypoglycemic AgentsImmune SystemInsulin-Like Growth Factor IInterleukin-1Interleukin 1 Receptor Antagonist ProteinInterleukin-6LipopolysaccharidesMacrophages, PeritonealCholecystokininHypoglycemic AgentsIL1RN protein, humanIl1rn protein, mouseInsulin-Like Growth Factor IInterleukin-1Interleukin 1 Receptor Antagonist ProteinInterleukin-6LipopolysaccharidesSialoglycoproteinsTumor Necrosis Factor-alphaVanadium Compoundsvanadyl sulfate

Identifiers

PMID16217019
PMCPMC1257721
OpenAlexW2126944350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.